Search results for "target"

showing 10 items of 1196 documents

The In Silico Fischer Lock-and-Key Model: The Combined Use of Molecular Descriptors and Docking Poses for the Repurposing of Old Drugs

2019

Not always lead compound and/or derivatives are suitable for the specific biological target for which they are designed but, in some cases, discarded compounds proved to be good binders for other biological targets; therefore, drug repurposing constitute a valid alternative to avoid waste of human and financial resources. Our virtual lock-and-key methods, VLKA and Conf-VLKA, furnish a strong support to predict the efficacy of a designed drug a priori its biological evaluation, or the correct biological target for a set of the selected compounds, allowing thus the repurposing of known and unknown, active and inactive compounds.

DrugComputer scienceIn silicomedia_common.quotation_subjectCombined useDrug repurposingComputational biology01 natural sciences03 medical and health scienceschemistry.chemical_compoundMolecular descriptorRepurposing030304 developmental biologymedia_common0303 health sciencesStatisticsDescriptorLock-and-key model0104 chemical sciences010404 medicinal & biomolecular chemistryDrug repositioningchemistryDocking (molecular)Biological targetMolecular dockingLead compound
researchProduct

Immunotoxicity of Therapeutic Antibodies and Nanoparticles.

2020

Therapeutic antibodies and nanotherapeutic drugs are of great concern due to their widespread use against numerous diseases worldwide. They are frequently used for targeted therapy under the assumption that they cause fewer side effects than nontargeted drugs. Despite their specificity and particular design for therapeutic actions, they might still exhibit unintended adverse effects in the immune system. Immunotoxicity reactions are mediated by immunomodulation, including immunostimulation and immunosuppression. The present review gives an overview on the adverse immunotoxic effects induced by therapeutic antibodies as well as nanotherapeutic drugs. In this context, future methods combining…

DrugCytotoxicity ImmunologicDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectImmunologyContext (language use)BioengineeringMonoclonal antibodyAntibodiesTargeted therapyImmunomodulationImmune systemImmunology and AllergyMedicineAnimalsHumansAdverse effectmedia_commonbusiness.industryImmunosuppressionTolerabilityDrug DesignImmune SystemImmunologyNanoparticlesbusinessCritical reviews in immunology
researchProduct

Dendrimers as Non-Viral Vectors in Gene-Directed Enzyme Prodrug Therapy.

2021

Gene-directed enzyme prodrug therapy (GDEPT) has been intensively studied as a promising new strategy of prodrug delivery, with its main advantages being represented by an enhanced efficacy and a reduced off-target toxicity of the active drug. In recent years, numerous therapeutic systems based on GDEPT strategy have entered clinical trials. In order to deliver the desired gene at a specific site of action, this therapeutic approach uses vectors divided in two major categories, viral vectors and non-viral vectors, with the latter being represented by chemical delivery agents. There is considerable interest in the development of non-viral vectors due to their decreased immunogenicity, higher…

DrugDendrimersmedicine.medical_treatmentmedia_common.quotation_subjectGenetic VectorsPharmaceutical ScienceEnzyme TherapyComputational biologyReviewdendrimerdelivery vehiclesAnalytical ChemistryTargeted therapyViral vectornon-viral vectorQD241-441DendrimerGDEPTDrug DiscoverymedicineAnimalsHumansProdrugsPhysical and Theoretical ChemistryGenemedia_commonchemistry.chemical_classificationGDEP therapyImmunogenicityOrganic ChemistrytransgeneGene Transfer TechniquesGenetic TherapyProdrugtargeted therapyEnzymesEnzymechemistrygene delivery systemChemistry (miscellaneous)Molecular MedicineNanoparticlesMolecules (Basel, Switzerland)
researchProduct

Core-crosslinked polymeric micelles: Principles, preparation, biomedical applications and clinical translation

2015

Polymeric micelles (PM) are extensively used to improve the delivery of hydrophobic drugs. Many different PM have been designed and evaluated over the years, and some of them have steadily progressed through clinical trials. Increasing evidence suggests, however, that for prolonged circulation times and for efficient EPR-mediated drug targeting to tumors and to sites of inflammation, PM need to be stabilized, to prevent premature disintegration. Core-crosslinking is among the most popular methods to improve the in vivo stability of PM, and a number of core-crosslinked polymeric micelles (CCPM) have demonstrated promising efficacy in animal models. The latter is particularly true for CCPM in…

DrugDrug targetingMaterials sciencemedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Pharmaceutical ScienceNanotechnologyBioengineeringMicelleArticleMaterials Science(all)In vivoGeneral Materials SciencePharmaceutical sciencesPolymermedia_commonMETIS-315279Translation (biology)3. Good healthNanomedicineTargeted drug deliveryIR-99653Drug deliveryNanomedicineCore-crosslinkingEPRMicelleBiotechnologyNano Today
researchProduct

Mechanism-based selection of compounds for the development of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP project.

2010

The 6th European Framework Programme project LIINTOP was specifically raised to optimise and provide established protocols and experimental in vitro models for testing intestinal and liver absorption, metabolism and toxicity of molecules of pharmacological interest. It has been focused on some of the most promising existing liver and intestine in vitro models with the aim of further improving their performance and thus taking them to a pre-normative research stage. Regarding the specific area of the liver, a first basic approach was the optimisation of in vitro hepatic models and the development and optimisation of in vitro approaches for toxicity screening. New advanced technologies have b…

DrugDrug-Related Side Effects and Adverse ReactionsMechanism (biology)media_common.quotation_subjectMechanism basedGeneral MedicineComputational biologyPharmacologyBiologyToxicologyModels BiologicalIn vitroLiverChemical agentsToxicity TestsMolecular targetsScreening methodAnimalsHumansChemical and Drug Induced Liver InjurySelection (genetic algorithm)media_commonToxicology in vitro : an international journal published in association with BIBRA
researchProduct

Design and development of hyaluronan-functionalized polybenzofulvene nanoparticles as CD44 receptor mediated drug delivery system

2017

A tri-component polymer brush (TCPB), composed of a polybenzofulvene copolymer bearing low molecular weight hyaluronic acid (HA) on the surface of its cylindrical brush-like backbone and oligo-PEG fractions, was employed in the preparation of 350 nm nanostructured drug delivery systems capable of delivering the anticancer drug doxorubicin. The obtained drug delivery systems were characterized on the basis of drug loading and release, dimensions and zeta potential, morphology and in vitro cell activity, and uptake on three different human cell lines, namely the bronchial epithelial 16HBE, the breast adenocarcinoma MCF-7, and the colon cancer HCT116 cells. Finally, the ability of doxorubicin…

DrugMaterials scienceAtomic and Molecular Physics and Opticmedia_common.quotation_subjectHyaluronic acidCD44 receptorBioengineering02 engineering and technologyPharmacology010402 general chemistry01 natural sciencesCD44 receptor; Doxorubicin; Hyaluronic acid; Nanomedicine; Polybenzofulvene; Tri-component polymer brush TCPB; Bioengineering; Chemistry (all); Atomic and Molecular Physics and Optics; Modeling and Simulation; Materials Science (all); Condensed Matter Physicschemistry.chemical_compoundAtomic and Molecular PhysicsHyaluronic acidTri-component polymer brush TCPBmedicineGeneral Materials ScienceDoxorubicinmedia_commonbiologyCD44Chemistry (all)General Chemistry021001 nanoscience & nanotechnologyCondensed Matter PhysicsAtomic and Molecular Physics and Optics0104 chemical sciencesNanomedicinechemistryTargeted drug deliveryDoxorubicinModeling and SimulationDrug deliveryCancer cellbiology.proteinBiophysicsNanomedicineMaterials Science (all)Polybenzofulveneand Optics0210 nano-technologymedicine.drug
researchProduct

Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives.

2009

Over the past few years, epidermal growth factor receptor has emerged as one of the most important targets in tumorgenesis and several drugs targeting signal transduction pathways have been developed. The first among these agents to be approved for the treatment of NSCLC was gefitinib, a potent, selective and reversible inhibitor of HER1/EGFR tyrosine kinase activity. The review summarizes its clinical development and the new therapeutic options, with particular focus on predictive markers of susceptibility to this drug.

DrugOncologyCancer Researchmedicine.medical_specialtyLung Neoplasmsmolecular markersmedia_common.quotation_subjectgefitinibAntineoplastic AgentsGefitinibcancer therapyGefitinibCarcinoma Non-Small-Cell LungInternal medicinetyrosine kinase inhibitorsmedicineAnimalsHumansgefitinib; non-small cell lung cancer (NSCLC); epidermal growth factor receptor (HER1/EGFR); tyrosine kinase inhibitors; target therapy; molecular markers; EGFR mutationsEpidermal growth factor receptorLung cancermedia_commonPharmacologyClinical Trials as Topicbiologybusiness.industrytarget therapymedicine.diseaseEGFR mutationsepidermal growth factor receptor (HER1/EGFR)ErbB Receptorsnon-small cell lung cancer (NSCLC)OncologyQuinazolinesbiology.proteinMolecular MedicineSignal transductionbusinessBiomarkersEgfr tyrosine kinaseSignal Transductionmedicine.drug
researchProduct

Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer

2014

Despite recent advances in understanding the cancer signaling pathways and in developing new therapeutic strategies, non-small cell lung cancer (NSCLC) shows grim prognosis and high incidence of recurrence. Insufficient dis- ruption of oncogenic signaling and drug resistance are the most common causes of tumor recurrence. Drug resistance, in- trinsic or acquired, represents a main obstacle in NSCLC therapeutics by limiting the efficacy both of conventional che- motherapeutic compounds and new targeted agents. Therefore, novel and more innovative approaches are required for treatment of this tumor. MicroRNAs (miRNAs) are a family of small non-coding RNAs that regulate gene expression by sequ…

DrugSettore MED/06 - Oncologia Medicamedia_common.quotation_subjectGene regulatory networkPharmaceutical ScienceAntineoplastic AgentsDrug resistanceBiologyBioinformaticsCarcinoma Non-Small-Cell LungmicroRNAmedicineAnimalsHumansLung cancerBiologymedia_commonPharmacology. TherapyCell cyclemedicine.diseaseMicroRNAsChemistryDrug Resistance NeoplasmChemotherapy lung cancer microRNA oncogenic pathways resistance targeted agentsCancer cellSignal transductionSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioBiotechnology
researchProduct

Therapeutic targeting of SNAIL, RKIP, and YY1 in tumor metastasis and drug resistance

2020

Abstract Cancer is the leading cause of deaths worldwide and is of great importance. Metastasis-inducing the majority of cancer related deaths is a principal problem in cancer treatment. Therefore, therapy regimes preventing metastasis formation are of prominent importance to improve the outcome of malignant diseases. The epithelial-mesenchymal transition (EMT) is a predominant process associated with the onset of metastasis and converts epithelial cells to mesenchymal cells. In this chapter, we concentrated on three proteins involved in the metastasis and EMT: RKIP, SNAIL, and YY1. Briefly, SNAIL and YY1 are overexpressed in many cancers, while RKIP is downregulated. Therefore, these prote…

DrugbiologyYY1business.industrymedia_common.quotation_subjectMesenchymal stem cellCancerSnailDrug resistancemedicine.diseaseTherapeutic targetingMetastasisbiology.animalmedicineCancer researchbusinessmedia_common
researchProduct

A Hyaluronic acid-pentamidine bioconjugate as macrophage mediated drug targeting delivery system for the treatment of Leishmaniasis

2015

Leishmaniasis is still a serious public health problem worldwide, especially in tropical areas where this infectious disease is endemic. The most severe form of the disease (i.e. visceral) can claim victims if left untreated and the few accessible drugs have several drawbacks including major side effects and parenteral administration. In this context, the investigation of new delivery modalities which might reduce the toxicity and increase the bioavailability of the drugs currently on the market represents a valid strategy to counter these problems. Herein we present the development of a macrophage mediated drug targeting delivery system by conjugating the anti-leishmanial drug pentamidine …

Drugbiologybusiness.industryGeneral Chemical Engineeringmedia_common.quotation_subjectLeishmaniasisGeneral ChemistryPharmacologymedicine.diseasebiology.organism_classificationchemistry.chemical_compoundchemistryTargeted drug deliveryInfectious disease (medical specialty)Hyaluronic acidMedicinePotencyLeishmania majorAMPHOTERICIN-B RESISTANCE DISCOVERY TOXICITY MICELLESbusinessPentamidinemedicine.drugmedia_common
researchProduct